-
Everest Medicines Receives $280 Million from Gilead’s Immunomedics Following Partnership Cancellation
•
China-based Everest Medicines (HKG: 1952) has announced a significant financial development, receiving a full upfront payment of USD 280 million from Immunomedics, Inc., now a wholly-owned subsidiary of Gilead Sciences, Inc (NASDAQ: GILD). This payment is in relation to the cancellation of a partnership established in 2019, which was focused…
-
Everest Medicines Receives $280 Million from Gilead Sciences for Partnership Cancellation
•
China-based Everest Medicines (HKG: 1952) has announced that it has received a full upfront payment of USD 280 million from Immunomedics, Inc., now a wholly-owned subsidiary of Gilead Sciences, Inc (NASDAQ: GILD). This payment is in relation to the cancellation of a previous 2019 partnership between the two firms, which…
